TCRLAS v2.0 · WORKING METHODOLOGY
Different technologies need different evidence.
AI/digital, MedTech/health, and industrial technologies face different constraints. v2 CVA and HSE remain independent of milestone assignment.
The comparisons below preserve the earlier supplied domain document as historical context. Its broad timings and risk patterns are not verified forecasts or legal guidance for a particular offering. Its previous scoring terminology is not the active v2 CVA rubric.
Read the historical domain-comparison PDF →Wide tables scroll horizontally.
| Dimension | AI / Digital | MedTech / Health | Industrial / Energy / Manufacturing |
|---|---|---|---|
| Time to market | Fast (months) | Slow (years) | Medium (1–3 years) |
| Regulatory burden | Low–medium | Very high | Medium |
| Capital intensity | Low | High | Medium–high |
| IP defensibility | Weak–medium | Strong | Medium |
| Failure mode | Easy to launch, easy to copy | Hard to launch; late failure is difficult | Pilot works, scale breaks |
| Typical bottleneck | IP & defensibility | Regulation & validation | Reliability & integration |
| Critical guide levels | 3–5 | 4–7 | 5–7 |
Wide tables scroll horizontally.
| Domain | Path & risk | Source bottleneck |
|---|---|---|
| AI / Digital | Fast progression; may reach Level 3 quickly. Model performance can be mistaken for product readiness. | “The model works, so the product is ready.” |
| MedTech / Health | Slow, conservative exploration; regulation and IP clarity matter from early design. | “We’ll worry about regulation later.” |
| Industrial / Energy / Manufacturing | Engineering feasibility may be realistic, but integration is easily underestimated. | “If it works in the lab, it will work in the field.” |
Wide tables scroll horizontally.
| Domain | Path & risk | Source bottleneck |
|---|---|---|
| AI / Digital | User feedback is accessible; willingness to pay and IP strength are harder to establish. | Source limiter: Levels 3–4, IP strength. |
| MedTech / Health | Clinical validation dominates and the regulatory pathway gates progress. | Source limiter: Levels 4–5, regulatory readiness. |
| Industrial / Energy / Manufacturing | Pilots expose hidden failures; adoption depends on trust. | Source limiter: Levels 5–6, technical robustness and adoption logic. |
Wide tables scroll horizontally.
| Domain | Path & risk | Source bottleneck |
|---|---|---|
| AI / Digital | The source emphasizes scaling and intense competition; defensibility shifts toward data, brand, and execution speed. | Source stall: Levels 6–7, difficulty building a moat. |
| MedTech / Health | The source describes slow adoption after approval, high switching costs, and the burden of clinical trial cost and time. | Source stall: Levels 6–7, clinical trial cost and time. |
| Industrial / Energy / Manufacturing | Scale demands operational excellence, reliable manufacturing, and service; failure is costly and sales cycles are long. | Source stall: Levels 7–8, manufacturing, reliability, and service. |
Wide tables scroll horizontally.
| Dimension | AI / Digital | MedTech / Health | Industrial / Energy / Manufacturing |
|---|---|---|---|
| Technical Maturity | Model accuracy is not production reliability. | Clinical safety and reproducibility dominate. | Robustness under harsh conditions is key. |
| Market Validation | Interest is easier to obtain than payment. | Users may want it, while institutions decide. | Conservative users need time to trust it. |
| IP Strength | The source emphasizes data and execution over weak patent protection. | The source emphasizes patents and regulatory exclusivity. | Process and know-how protection matter. |
| Business & Team | Teams may be technology-heavy and sales-light. | Clinical and regulatory leadership are needed. | Engineering and operations leadership are needed. |
| Funding & Resources | Early bootstrapping may be possible; later competition can be demanding. | Capital needs intensify from the middle stages. | Pilot funding may be easier than scale funding. |
Wide tables scroll horizontally.
| Domain | Guide levels | Constraint | Practical focus |
|---|---|---|---|
| AI / Digital | 3–4 | Weak IP or unclear moat | Explore defensibility early. |
| MedTech / Health | 5–6 | Regulatory and clinical cost | Map regulation from day one. |
| Industrial / Energy / Manufacturing | 6–7 | Scale, reliability, and integration | Validate real-world robustness before scaling. |
Healthcare includes products and services.
Wellness, devices, medicines, diagnostics/laboratories, digital health, telehealth, clinical care, home health and medical logistics each need context-sensitive review. Unknown categories require classification review; no category selection creates permission.